Stockscreener 앱 받기
501.68
1.17%
5.80
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Short Covering: Is Madrigal Pharmaceuticals Inc benefiting from innovation trendsRate Hike & Weekly High Conviction Trade Ideas - baoquankhu1.vn
EULAV Asset Management Buys 20,000 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Lobbying Update: $80,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Madrigal Pharmaceuticals (NASDAQ:MDGL) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
SG Americas Securities LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals stock maintains Buy rating at Goldman Sachs By Investing.com - Investing.com Canada
Director Friedman sells Madrigal (MDGL) shares for $154,347 By Investing.com - Investing.com Canada
Rebecca Taub sells Madrigal (MDGL) shares worth $9.6 million By Investing.com - Investing.com Canada
JPM26: Madrigal seeks early dominance in MASH through strategic acquisitions - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Paul Friedman Sells 24,520 Shares - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells $9,617,384.00 in Stock - MarketBeat
MADRIGAL PHARMACEUTICALS Executives Sell Over $21 Million in Company Stock - TradingView — Track All Markets
Madrigal Pharmaceuticals (BIT:1MDGL) Price Target Increased by 11.17% to 537.90 - Nasdaq
ETF Watch: Is Madrigal Pharmaceuticals Inc a top pick in the sectorJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
How Madrigal Pharmaceuticals Inc. (MDGL) Affects Rotational Strategy Timing - Stock Traders Daily
MDGL Secures Exclusive Global Right for MASH Treatment From PFE - Finviz
Madrigal Pharmaceuticals stock bolstered by Truist’s positive view on Pfizer asset acquisition - Investing.com Canada
Madrigal Pharmaceuticals (MDGL) Stock Analysis: Strong Buy Ratings and a Promising 19% Upside Potential - DirectorsTalk Interviews
Roblox, First Solar, And League Enterprise Are Among Top 10 Large Cap Losers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? - Benzinga
Pfizer inks licensing deal with Madrigal for MASH candidate - MSN
Madrigal’s $50M Pfizer Deal Sparks a New MASH Drug Power Play - MyChesCo
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum - Yahoo Finance
Madrigal expands its MASH pipeline - The Pharma Letter
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe DowngradeWhat's Changed - Yahoo Finance
Is Madrigal Pharmaceuticals Inc. stock a safe investment in uncertain marketsPortfolio Value Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Madrigal Pharmaceuticals (MDGL) Secures Global License for Ervog - GuruFocus
Madrigal expands its mash pipeline with exclusive global license agreement for ervogastat - marketscreener.com
Pfizer in pact with Madrigal for MASH drug (MDGL:NASDAQ) - Seeking Alpha
Madrigal licenses Pfizer’s DGAT-2 inhibitor to expand MASH pipeline - Investing.com
Madrigal licenses Pfizer’s DGAT-2 inhibitor to expand MASH pipeline By Investing.com - Investing.com India
Madrigal Pharmaceuticals Expands Pipeline with Exclusive License Agreement for Ervogastat, Enhancing Leadership in MASH Therapies - Quiver Quantitative
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor - marketscreener.com
Drug combo planned to target liver fat in patients with MASH - Stock Titan
What Madrigal Pharmaceuticals (MDGL)'s Valuation-Driven Analyst Downgrade Means For Shareholders - Sahm
US Stocks Recap: How Madrigal Pharmaceuticals Inc YDO1 stock trades pre earningsShare Buyback & Smart Swing Trading Alerts - moha.gov.vn
Is Madrigal Pharmaceuticals Inc. stock positioned for digital transformationOil Prices & Risk Managed Investment Entry Signals - ulpravda.ru
Is Madrigal Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Rallies & Community Trade Idea Sharing Platform - ulpravda.ru
Will Madrigal Pharmaceuticals Inc. stock deliver better than expected guidance - ulpravda.ru
How Madrigal Pharmaceuticals Inc. (YDO1) stock trades pre earningsJuly 2025 Highlights & Verified Momentum Watchlists - ulpravda.ru
Why Madrigal Pharmaceuticals stock slumped on Tuesday - MSN
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday - Finviz
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.4%Time to Sell? - MarketBeat
Madrigal Pharmaceuticals (MDGL) Downgraded Amid Valuation Concer - GuruFocus
Wolfe Research downgrades Madrigal Pharmaceuticals stock on valuation concerns By Investing.com - Investing.com Canada
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - Finviz
Assessing Madrigal Pharmaceuticals (MDGL) Valuation As Rezdiffra Revenue Tops US$1b Amid Intensifying MASH Competition - Sahm
Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data (NASDAQ:MDGL) - Seeking Alpha
Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade - Seeking Alpha
MASH Treatment Market Competition Analysis 2025: How Players Are Shaping Growth - EIN News
4.73%
0.92%
자본화:
|
볼륨(24시간):